Back to News
Market Impact: 0.48
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
Source: zacks.com
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Acadia Pharmaceuticals shares fell 13% after its Alzheimer's psychosis study narrowly missed its primary endpoint. Results from the 60 mg dose were sufficiently supportive for the company to continue Phase III development, tempering—but not eliminating—the negative read-through from the failed primary goal.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
ACAD-0.82
More News
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- ‘U.S. trade policy is damaging the U.S. auto industry’: Canada’s purchase of American cars hits new low as Trump’s tariffs backfire on U.S. automakers
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Beware borrowing costs: The jump in yields could hit these debt-laden stocks the most
- US court upholds Pentagon’s blacklisting of Anthropic